Despite the usefulness of high-throughput screening in drug discovery, for some systems, low assay throughput or high screening cost can prohibit the screening of large numbers of compounds. In such cases, iterative cycles of screening involving active learning (AL) are employed, creating the need for smaller "informer sets" that can be routinely screened to build predictive models for selecting compounds from the screening collection for follow-up screens.
INTRODUCTION Over the past three decades, high-throughput screening (HTS) has become a well-established method used during early drug discovery. [1] [2] [3] [4] [5] [6] [7] However, low assay throughput or high screening cost can at times prohibit the screening of large numbers of compounds. 8, 9 Given this drawback, iterative cycles of design-screen-refine involving active learning (AL) strategies can be used when only a small number of compounds can or should be screened. [10] [11] [12] This, in combination with recent advances in machine learning, has recently prompted efforts to improve bioactivity modeling in order to identify active compounds in silico, with the aim of increasing the hit rates in compound screens. 11 For this purpose, a high-throughput screening fingerprint (HTS-FP) was developed by Petrone et al. 13 and later by Dančik et al., 14 which profiles compounds according to their bioactivity across a range of HTS assays. This work was based on the idea that such fingerprints are predictive of compound affinity on targets not covered in the fingerprint and showed the value of HTS-FP for virtual screening and biodiverse selection of actives. This concept has previously been explored computationally on smaller datasets, [15] [16] [17] [18] but without large-scale experimental validation. More recently, Riniker et al. 19 benchmarked the predictive performance of chemical fingerprints and HTS-FP in conjunction with a variety of classification methods across a large number of assays performed in Novartis and those in the public domain (available in PubChem). 20 It was found that random forest (RF) methods with HTS-FP often outperformed machine learning methods developed on chemical descriptors. 19 On a related note, Maciejewski et al. 21 explored an experimental design strategy where AL was used to enhance the chemical diversity of large training sets comprising over 50,000 compounds, leading to improvement in model performance. While the mentioned studies addressed the dependence of the model on 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 descriptor and classification method used, a comprehensive assessment of how the composition of the initially screened compound set (training set) affects model performance and early retrieval of actives from the remaining screening collection was not performed.
The effectiveness of HTS screening sets in identifying actives has been widely discussed. 22 Given the possible existence of over 10 63 drug-like molecules, 7 it is remarkable that HTS campaigns comprising "only" 10 6 compounds succeed in finding hits at all. [22] [23] [24] A plausible explanation for this is that screening libraries are not random, but rather biased towards biogenic compounds, likely to interact with the druggable proteome. This claim has been reinforced by studies showing the chemical similarity between metabolite space, natural product space and bioactive space. [25] [26] [27] A comprehensive analysis by Klekota et al. 28 showed that certain "privileged" chemical substructures, such as benzodiazepines, 29 enrich for bioactivity, creating further avenues for modeling the likelihood of compounds being bioactive in any therapeutically relevant setting (hereafter referred to as joint bioactivity modeling), rather than target-or phenotype-specific bioactivity modeling (also shown by Gillet et al.) . 30 In this study, we harnessed bioactivity information from a large number of PubChem 20 HTS assays to derive an assay-agnostic "informer compound set" that, once screened, predicts bioactivity better than randomly selected sets for almost all HTS assays, improving the efficiency of subsequent screens. We used AL to iteratively derive this set. Due to the difficulty in implementing AL under extreme class imbalance 31 as is the case for all HTS assays analyzed in this study, activities from multiple assays were combined to derive binary labels representing assay-agnostic bioactivity for each compound. This was based on the idea of joint bioactivity modeling 28, 30 and led to a class-balanced dataset suitable for AL. HTS-FPs were used as descriptors, as they showed improved performance over chemical fingerprints. 19 Moreover, this Page 4 of 39 Information and Modeling   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   5 informer set was constructed with the aim to facilitate routine screens, as pre-composed sets are easier to screen routinely from an infrastructure point of view.
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Related studies by Young et al. 32 and Taylor 33 describe screening strategies aimed at increasing the chances of finding active compounds by predictive modeling using extreme value theory (validated on ~75k data points in a single cell-based assay) and intelligent sampling methods (validated on 2k data points), respectively. However, our study differs considerably, as we validate our method on over 10,000,000 HTS data points across a wide range of assay biology, and use descriptors based on a large amount of bioactivity data, hereby significantly increasing predictive power. Information and Modeling   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 6
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METHODS
HTS data
The public HTS data used by Riniker et al. 19 was used in this study (see Tables S1 and S2 of this reference for the list of assays used). HTS data from the NIH molecular libraries program (MLP) comprising at least 300,000 compounds per assay, and submitted by the NCGC, the Scripps Research Institute Molecular Screening Center, or the Burnham Center for Chemical Genomics were extracted from PubChem. 20 This resulted in a total of 141 cell-based and targetbased assays (mainly using fluorescence readout technologies), covering a wide range of assay biology (kinases, proteases, ion channels, GPCRs and other target classes). Assay-specific zscores were calculated for all compounds tested based on the activity measurement used to define the PubChem activity outcome. The set of assays was subsequently split into 2 groups: 95 "group 1 assays" (comprising over 338,000 compounds) and 46 "group 2 assays" (comprising 300,000-338,000 tested compounds, depending on operational turnover of the compound collection at the screening centers). Group 1 assays (referred to as "historical assays" by Riniker et al.) 19 were used exclusively for the construction of HTS-FP, 13 a fingerprint used as a descriptor for machine learning, profiling the activity of a compound across HTS assays based on z-scores (float version). 13 Group 2 assays (referred to as "test assays" by Riniker et al.) 19 were used for deriving labels and for model training and testing. This distinction between assay groups ensured that there was no overlap in targets between the two groups. 19 
HTS-FP
For each compound, an HTS-FP was computed, in which each element corresponds to the zscore (based on activity) of the compound in one of the group 1 assays. Missing z-scores (15% of all data points; not every compound is tested in each assay) were assumed to be 0 (the mean of zscores), as implemented earlier by Riniker et al. 19 Workflow In this study we tested the performance of bioactivity models developed on an informer set derived with AL. As this set was iteratively augmented, the informer set is available at multiple sizes from 1,000 to the maximum size of the AL set (when AL is terminated). First, we evaluated the performance for predicting bioactivity independent of tested assay (Figure 1 , joint bioactivity modeling). 
Assay-specific validation
Add random subset of uncertain compounds (1, 250) Here, activities from group 2 assays were combined to derive binary labels representing assayagnostic bioactivity for each compound in order to construct a class-balanced dataset suitable for AL. Improved model performance at this step was considered a prerequisite for the more challenging task of predicting actives for individual assays. An assay-specific validation was performed to address the latter task: the informer set was derived from activity data from 45 group 2 assays and predictivity was assessed on the one assay remaining (Figure 1 , assayspecific validation). This was repeated 46 times, effectively leaving each group 2 assay out once.
Joint bioactivity modeling
The 1,000 least and most active compounds (based on z-scores) were selected from each group 2 assay, resulting in a total of 58,768 compounds. A skewed distribution of the number of assays these compounds were active in was observed, with 45%, 33%, 12% and 10% of compounds active in 0, 1, 2 and more than 2 assays, respectively (Supplementary Figure S1 ). Each compound was labeled as "active" if it was active in any of the group 2 assays (as defined by the PubChem activity outcome) or "inactive" otherwise, resulting in a total of 32,171 actives and 26,597 inactives. This labeling was based on the concept of considering activities independent of the assay they were tested in (joint bioactivity). An RF model (scikit-learn) [34] [35] [36] was developed on a randomly selected class-balanced training set of 5,000 compounds (to initiate training), and the performance of the model was assessed on the remaining compounds. Using AL, this training set was iteratively augmented with up to 1,250 uncertain samples at each iteration, with the aim to improve model performance on the remaining compounds (see "Active learning" section for more details). The model for this training set, the informer set, was benchmarked against a model 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   9 developed on a randomly selected set at each set size using the area under the receiver operating characteristic curve (ROCAUC).
Assay-specific validation
Here, the informer set was derived from activity data from 45 group 2 assays, and a model was trained on group 1 assay HTS-FPs and labels derived from the one assay left out. The performance of the model was assessed on the compounds in the assay left out minus those present in the informer set. The starting set for training initiation was a class-balanced set of 1,000 compounds comprising 500 actives and 500 inactives, both selected randomly from the compounds available in the assay left out. This set was iteratively augmented by up to 500 compounds using AL (see "Active learning" section for more details). The size of the training and augmentation set was kept smaller here than for the joint bioactivity modeling due to observed improvement in performance at the earlier stages of the algorithm. Performance on the assay left out was assessed at each set size using the ROCAUC, the area under the precisionrecall curve (PRAUC), 37 Boltzmann-enhanced discrimination of ROC (BEDROC) (α=100), 38, 39 and the retrieval of Murcko scaffolds 40 belonging to the active compounds. The BEDROC(α=100) was used due to its relevance in early retrieval of actives in imbalanced datasets and the PRAUC was used because it captures the effect of the large number of inactive compounds on the model's performance. 37 Both these metrics were therefore considered more relevant than the ROCAUC for the assay-specific validation (by contrast, for the joint bioactivity modeling the ROCAUC was considered an adequate metric due to class balance).
The model was benchmarked against models developed on a randomly selected set and a set comprising compounds with the highest median z-scores across the 45 assays left in (the frequent 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 hitter set). The randomly selected set was sampled across Murcko scaffolds: 40 Murcko scaffolds 40 were randomly selected, followed by the selection of one compound per scaffold.
This was performed to avoid undersampling low-density areas of chemical space. The comparison with the frequent hitter set was included to ensure that the performance gain for the informer set was better than when simply more actives from other assays (including more frequent hitters) were trained on.
Machine learning
The RF parameters used were: 100 trees (maximum depth = 10), minimum samples to split = 4, and minimum samples for a leaf = 4, random state = 12345.
Active learning (AL)
The AL approach consisted of three iterative steps: (1) 
with SU c in the range of 0-1 where 0 and 1 represent the most uncertainty and complete certainty in prediction, respectively. Only samples with an SU value smaller than the uncertainty threshold 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 11 (UT) were considered uncertain. We investigated the effect of varying the UT from 0.5 (least stringent) to 0.01 (most stringent) for the joint bioactivity modeling, and used a UT of 0.1 for the assay-specific validation. The presence of uncertain samples suggests undersampling of bioactivity space. Including these samples could improve model performance over random sampling. 10
Software used
The workflow comprised Python scripts for data analysis, using scikit-learn 36 for machine learning and RDKit 41 for scaffold derivation. Tableau 42 was used for data exploration and R 43 was used for the visualization of results. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 12
RESULTS AND DISCUSSION
The development of an informer set for the prediction of joint bioactivity is presented first (see Figure 1 -left). Prediction of joint bioactivity allowed the identification of compounds more likely to be bioactive regardless of the assay used. This was followed by a performance assessment of the informer set on individual assays (assay-specific validation; see Figure 1 right), and an analysis of scaffold retrieval and set composition. The assay-specific validation was performed in order to determine whether the informer set is more useful than a randomly selected set in predicting actives for novel assays one might perform.
Joint bioactivity modeling
The gap in ROCAUC between models developed on the AL sets and on randomly selected sets consistently widens from set sizes of ~5,000 onwards (see Figure 2 -top). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   14 process. For set sizes between 10,000 and 20,000, the number of uncertain samples is larger for the AL (UT = 0.1) set than for the randomly selected set. However, for set sizes larger than 22,000, the number of uncertain samples declines faster for the AL (UT = 0.1) set than for the randomly selected set (Figure 2 -bottom) , and reduces to zero earlier. For example, almost all uncertain samples were exhausted for a set size of approximately 35,000 using AL, whereas the random set did not exhaust the uncertain samples even at set sizes upwards of 50,000. In conjunction with an observed performance gain across all set sizes for the AL sets, this indicates the benefit of AL in sampling relevant bioactivity space more efficiently, hereby improving the identification of compounds bioactive in one or more group 2 assays. For further analysis, we chose a UT value of 0.1 on the basis of a trade-off between gain in performance and maximum training set size.
Predictive performance of informer set on individual assays
In an attempt to translate performance gain in predicting joint bioactivity (see previous section) to performance gain in individual large-scale assays, we performed an assay-specific validation for all group 2 assays. Improved predictive performance in this setting would corroborate the usefulness of an informer set, as no prior information about the assay left out would be required for its construction.
The BEDROC(α=100), 38, 39 PRAUC and ROCAUC were calculated for an RF classifier trained on the informer set (AL), a randomly selected set, and the frequent hitter set. These values were averaged over all 46 assay-specific validation experiments and were binned by set size (see 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 58 59 60 set size are shown for all three training sets (bin width=500). The assay-averaged performance for the AL set (all metrics) is consistently better than that for the randomly selected set. For the frequent hitter set, performance is consistently worse than both the AL set and the randomly selected set for training sets larger than 5,000 compounds.
These results indicate that models trained on the AL set consistently retrieve more actives compared to models trained on the other sets.
The frequent hitter set was used as a benchmark, to ensure that the performance gain of the AL set was better than when simply more actives from other assays (including more frequent hitters) were trained on. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 16
Overall, the performance for the AL set was enhanced compared to the randomly selected set, with an average increase of 0.024, 0.014 and 0.016 in average BEDROC, PRAUC and ROCAUC, respectively (all with paired t-test p-values < 10 -15 ). The apparent low values of the average BEDROC (0.25-0.40) can be explained by the Boltzmann enhancement, as early retrieval of actives is strongly preferred. Low values of the average PRAUC metric (0.10-0.25) can be explained by the extreme class imbalance: a random classifier would achieve a PRAUC of ~0.007 given the average fraction of actives is only ~0.7%.
For the frequent hitter set, performance is consistently worse for set sizes larger than 5,000, indicating that simply including more actives from other assays does not account for the performance gain observed for the informer set. This finding is in line with the results of the "weak reinforcement strategy" as described in the study by Maciejewski et al. 21 Here, training sets with a large number of actives similar in descriptor space (including frequent hitters 44, 45 in our study, as the descriptor space is based on bioactivity profiles) were found to be poor at identifying the remaining small number of actives in the test set due to insufficient coverage of descriptor space. By contrast, training sets containing compounds outside the applicability domain, corresponding to uncertain samples in this study, were much better at identifying the remaining actives in the screening collection.
Next, the average improvement in performance over all set sizes of the informer set was calculated separately for each assay (see Figure 4 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 18 phosphatase in mouse), 463210 (caspase 7) and 463141 (caspase 3), with BEDROC improvements of 0.11, 0.11, 0.09 and 0.06, respectively. By contrast, a significant drop of 0.09 in BEDROC was observed for assay number 493011 (DNA deaminase APOBEC-3A). While improvement was modest for most assays, it was consistent, as shown by the error bars representing the standard error of the mean difference in performance between the informer set and the randomly selected set across all sizes. Given the relatively small training sets, varying in size from ~0.3% to 10% of the entire screening collection, large improvements in predictive power over the remaining 90%-99.7% would be unrealistic. We attempted to investigate the cause for the performance loss for the remaining 8 assays, but could not find an explanation: there was no apparent relationship with the average performance for that assay, nor the number of actives in that assay.
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Scaffold retrieval for individual assays
We analyzed the scaffold retrieval rate (defined as the retrieved percentage of unique scaffolds belonging to active compounds in the test set; see Figure 5 -top) and the median z-scores (see Figure 5 -bottom) of actives identified in the top 5% ranked compounds in order to assess whether these actives were enriched for frequent hitters. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 A consistently higher scaffold retrieval for the AL set, and similar median z-scores (~0.20) for the AL set and the randomly selected set were observed. This indicates that the AL approach improves the retrieval of diverse sets of active compounds, while not enriching for frequent hitters. The frequent hitter set consistently shows worse performance than the other two sets in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 20 scaffold retrieval. In addition, the median z-score of the actives retrieved consistently drops from 0.09 to below 0 ( Figure 5 -bottom) . The latter drop is likely caused due to fewer compounds with high median z-scores remaining in the test set as training set size increases. Relative stability of the median z-score is observed for both the AL and random sets, indicating no enrichment for frequent hitters in the training set. In summary, we conclude that when the AL approach is used the scaffold retrieval is improved, frequent hitters are not enriched for and at the same time overall hit rates are improved.
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Composition of informer set
In order to analyze the composition of the informer set in more detail, we calculated the fraction of the number of active compounds picked from the group 2 assays relative to the number of active compounds for each assay (see Figure 6 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 . While the AL approach improves performance for most of the assays mentioned above (see Figure 4 ), interestingly, the average BEDROC is higher for those assays of which the active compounds are overrepresented (0.50) than for the assays of which the active compounds are underrepresented (0.29). This indicates that more actives are picked from assays already exhibiting good performance.
We attempted to investigate whether bias towards active compounds from particular assays in the informer set was related to improvement in performance over models trained on randomly selected sets for those assays, but could not find any link. We therefore conclude that this 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 22 improvement in performance is due to better sampling of bioactivity space, as the AL approach iteratively augments the informer set with uncertain samples. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 23 CONCLUSION Strategies involving iterative cycles of feedback-driven compound selection and testing can be used when low assay throughput or high screening cost hinders the screening of large compound libraries. This creates the need for the exploratory screening of smaller informer sets to build predictive models for compound selection for follow-up testing. In this study, we performed a data-driven construction of an informer compound set with improved retrieval of actives in a subsequent selection round for apparently unrelated HTS assays. The benefit of this informer set was validated over randomly selected training sets on 46 PubChem 20 assays comprising at least 300,000 compounds. Overall, we highlight that such a set -of adjustable size, depending on the number of compounds one intends to screen -can be employed for routine exploratory screening in an assay-agnostic fashion for a gain in predictive power.
Averaged over all assays, an improvement in BEDROC, PRAUC and ROCAUC (of 0.024, 0.014 and 0.016, respectively) was observed with respect to random training sets, all with paired t-test p-values < 10 -15 . The informer set improved the BEDROC for 38 out of 46 assays, indicating better early retrieval of actives. In addition, we found that our approach improved the retrieval of diverse sets of active compounds, while not enriching for frequent hitters, as scaffold retrieval was enhanced and the median z-score activity of the actives retrieved was unaffected.
The informer set overrepresented actives from certain assays, and underrepresented actives from other assays. Interestingly, while the informer set increased performance for both groups of assays, the BEDROC was higher (0.50) for the assays of which the actives were overrepresented, than for assays with underrepresented actives (0.29). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 24
We conclude that our AL approach is able to more effectively sample descriptor space, expected to improve the retrieval of active compounds in subsequent screens, thereby reducing the time and expense required to arrive at the same number of hits. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 25 ASSOCIATED CONTENT Supporting Information.
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